The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F16%3A00113805" target="_blank" >RIV/00216224:14110/16:00113805 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/16:00063636

Výsledek na webu

<a href="https://insights.ovid.com/article/00001721-201606000-00003" target="_blank" >https://insights.ovid.com/article/00001721-201606000-00003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MBC.0000000000000438" target="_blank" >10.1097/MBC.0000000000000438</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting

Popis výsledku v původním jazyce

Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B-2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B-2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P&lt;0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Název v anglickém jazyce

The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting

Popis výsledku anglicky

Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B-2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B-2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P&lt;0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BLOOD COAGULATION &amp; FIBRINOLYSIS

ISSN

0957-5235

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

370-373

Kód UT WoS článku

000375857700003

EID výsledku v databázi Scopus

2-s2.0-84947461597